Drug Database
TA

tacrolimus (Protopic / tacrolimus, topical / M 1151C2)

✓ Approved

Roche · FKBP1A

什么是 tacrolimus?

tacrolimus 是一种治疗药物,由Roche研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名Protopic, tacrolimus, topical, M 1151C2
公司Roche
分子靶点FKBP1A
给药途径Topical
状态Approved

作用机制

分子靶点

tacrolimus 作用于 1 个分子靶点:

FKBP1AFKBP prolyl isomerase 1A (FKBP-12, FKBP12)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

tacrolimus 针对 3 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersDermatitis allergic✓ Approved
Skin and subcutaneous tissue disordersDermatitis atopic✓ Approved
Skin and subcutaneous tissue disordersPsoriasisPhase II

相关研究文献

PubMedExpert opinion on drug delivery2026-11-19

Dissolving and hydrogel-based polymeric microneedles for bacterial keratitis: materials, therapeutic payloads, design-performance relationships, and future perspectives.

Peirovi Babak B, Amanzadi Bentolhoda B, Censi Roberta R, Aghamollaei Hossein H

Bacterial keratitis (BK) is a major cause of corneal visual impairment. Although topical antibiotics remain the mainstay of treatment, tear turnover, blinking, nasolacrimal drainage, and the corneal epithelial barrier limit drug residence and penetration. Polymeric microneedles, particularly dissolving and hydrogel-based systems, may enhance ocular residence of therapeutic agents and enable controlled or sustained drug release. This review summarizes corneal anatomy and ocular drug-delivery barriers, outlines the pathophysiology of bacterial keratitis, and evaluates microneedle platforms developed for ocular applications, with emphasis on dissolving and hydrogel-based polymeric systems for bacterial keratitis. A focused search of PubMed, Scopus, and ScienceDirect was undertaken, supplemented by a search of Google Scholar to identify additional relevant studies. Relevant studies were compared according to polymer composition, microneedle dimensions and density, penetration depth, dissolution or swelling, and release kinetics. Polymer design-property relationships, including the effects of concentration, molecular weight, crosslinking, biodegradability, and post-administration polymer fate, are also discussed. Polymeric microneedles offer a promising strategy for overcoming corneal delivery barriers, but clinical translation will depend on reproducible manufacturing, mechanical and ocular safety, sterilization and storage stability, user-friendly application, and robust clinical evidence demonstrating advantages over optimized topical therapies.

PMID 43053713
阅读全文 →
PubMedCell death discovery2026-11-19

CaMK4 drives pathogenic Th17 cell response via the STAT3/RORγt axis in psoriasis.

Ge Huiyao H, Zhang Xinwen X, Chen Mei M, Ren Yan Y et al.

Psoriasis is a chronic inflammatory skin disease driven by dysregulated immune responses, particularly those mediated by pathogenic Th17 cell response; however, the key intracellular signaling molecules that specifically regulate Th17 cell pathogenicity in the skin remain incompletely defined. Here, we showed that CaMK4 was highly expressed in CD4+ T cells from psoriatic lesional skin in both humans and mice. T cell-specific Camk4 deletion alleviated imiquimod (IMQ)-induced psoriasiform dermatitis, accompanied by reduced epidermal hyperplasia and decreased frequencies of skin RORγt⁺ and IL-17A⁺ CD4⁺ T cells. Mechanistically, CaMK4 mediated IL-23-triggered phosphorylation of STAT3, which promoted the expression of RORγt and IL-17A in CD4⁺ T cells. In vivo, reconstitution of STAT3 activity restored psoriasiform dermatitis in T cell-specific Camk4-deficient mice. Furthermore, topical application of a CaMK4 inhibitor ameliorated IMQ-induced skin pathology. Clinically, CAMK4 expression positively correlated with RORC and IL17A levels in CD4⁺ T cells from psoriasis patients, and inhibition of CaMK4 suppressed IL-23-induced Th17 cell response both in patient-derived CD4⁺ T cells and in ex vivo human skin explants. These findings identify CaMK4 as a critical driver of pathogenic Th17 cell response via the STAT3/RORγt axis in psoriasis and suggest that it may represent a potential target for further therapeutic exploration.

PMID 43052244
阅读全文 →
PubMedAesthetic surgery journal2026-11-19

Determining the Appropriate Age for Aesthetic Procedures in Minors: A Review of the Guidelines, Outcomes, and Ethical Considerations.

Gimenez Lynch Carlota C, Munkwitz Sara E SE, Smith Kierstyn K, Shah Hana H et al.

Adolescents seeking aesthetic procedures present unique clinical and ethical challenges because they exist within an evolving stage of cognitive, emotional, and physical development. Although legal frameworks generally require parental consent for minors, determining procedural appropriateness extends beyond consent alone. It also requires careful consideration of psychosocial maturity, motivation, and long-term well-being. Perspectives regarding cosmetic procedures in minors vary widely, particularly because many interventions are performed to improve appearance or psychosocial distress rather than treat a clearly defined medical condition. This review synthesizes current evidence regarding regulatory considerations, safety outcomes, and ethical principles surrounding non-surgical and surgical aesthetic procedures in minors. Common non-surgical procedures include topical skincare regimens, injectables, lasers, skin resurfacing, and microneedling. Commonly performed surgical procedures include otoplasty, rhinoplasty, breast reduction, breast augmentation, and other body contouring interventions. Throughout the literature, there is substantial variability in minimum age recommendations, professional guidance, and procedural oversight across procedures and countries. However, prior studies have generally demonstrated favorable safety profiles, high postoperative satisfaction, and psychosocial improvement in appropriately selected adolescent patients. Given the absence of standardized age requirements for many procedures, surgeons bear substantial responsibility in determining procedural appropriateness on an individualized basis. Careful assessment of emotional maturity, body image, social influences, motivation, and understanding of procedural risks and limitations is therefore critical when evaluating minors seeking aesthetic intervention.

PMID 43053604
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Calcium-Based Antimicrobial Peptide Compounds as a Novel Treatment for Chronic Cheilitis: A Controlled Clinical Trial.

Ji Hyunsuk H, Cai Tao T, Chen Shuang S, Xiong Jianxia J et al.

Chronic cheilitis refers to recurrent inflammation of the lips lasting for 3 months or longer. Commonly managed with topical corticosteroids or tacrolimus; however, these medications carry a risk of side effects. Calcium-based antimicrobial peptide compounds (CAPCS) contain natural calcium derivatives and antimicrobial peptides that provide anti-inflammatory and barrier-supporting effects. We explored whether CAPCS lip balm could serve as an alternative to tacrolimus 0.03% for treating chronic cheilitis. A total of 52 patients with chronic cheilitis participated in this double-blind, controlled trial and were allocated to use CAPCS lip balm (n = 26) or 0.03% tacrolimus ointment (n = 26) for a period of 4 weeks. Clinical assessments were performed at baseline, Week 2, and Week 4. A 3-month follow-up visit was conducted to evaluate recurrence or sustained improvement. Forty-five patients completed the 4-week treatment. Both groups showed marked improvement from baseline by Week 4 (p < 0.001), although the tacrolimus group showed a faster reduction at Week 2 (4.4 ± 4.3 vs. 6.7 ± 4.0, p = 0.028). CAPCS showed good tolerability, with two cases of mild adverse events (7.7%), in contrast to six events (23.1%) observed in the tacrolimus group. At the 3-month follow-up, patients who continued CAPCS use showed sustained improvement, while recurrence was more common among those who stopped treatment. CAPCS lip balm demonstrated comparable efficacy to tacrolimus 0.03% ointment, was better tolerated, and may serve as a safe alternative or a maintenance option for chronic cheilitis.

PMID 43047289
阅读全文 →
PubMedPediatric transplantation2026-11-18

Disseminated Nocardia farcinica Infection Involving the Lungs, Central Nervous System, and Skeletal Muscle in a Pediatric Liver Transplant Recipient: A Case Report.

Liu Ying Y, Cai Ru-Zhou RZ, Qu Wei W, Zhu Zhi-Jun ZJ et al.

Nocardiosis is an uncommon but potentially life-threatening opportunistic infection in solid organ transplant recipients. Disseminated disease, particularly with central nervous system (CNS) involvement, may be difficult to recognize because clinical and radiological findings are nonspecific and conventional microbiological diagnosis can be delayed. We describe disseminated Nocardia farcinica infection involving the lungs, brain, and skeletal muscle in a pediatric liver transplant recipient. A 5-year-old boy underwent emergency auxiliary living-donor liver transplantation (LT) for acute liver failure of unknown etiology. Because the donor-recipient pair was ABO-incompatible, an anti-CD20 monoclonal antibody was administered intraoperatively, followed by tacrolimus, methylprednisolone, and mycophenolate mofetil. Six months after transplantation, while receiving tacrolimus 0.25 mg every 12 h, he presented with fever, cough, headache, nausea, vomiting, and a tender mass over the left lower leg; the tacrolimus trough concentration was 19.6 ng/mL. Chest computed tomography showed a cavitary pulmonary lesion, and an elevated 1,3-beta-D-glucan level initially raised concern for invasive fungal infection. Next-generation sequencing (NGS) of bronchoalveolar lavage fluid identified Nocardia farcinica. Brain MRI and MRI of the left lower leg subsequently demonstrated multiple cerebral abscesses and an anterior tibial muscle abscess, confirming disseminated nocardiosis. Treatment was changed to trimethoprim-sulfamethoxazole (TMP-SMX)-based combination antimicrobial therapy, with temporary interruption and subsequent reintroduction of tacrolimus at a lower target trough concentration. Clinical symptoms and radiological lesions progressively resolved, with no recurrence during long-term follow-up. In liver transplant recipients with pulmonary nocardiosis, especially when neurological or soft-tissue symptoms are present, early evaluation for dissemination is essential. Rapid molecular identification, prolonged antimicrobial therapy guided by clinical and radiological response and susceptibility data when available, serial imaging, and individualized adjustment of immunosuppression are central to successful management.

PMID 43046614
阅读全文 →
PubMedJFMS open reports2026-11-18

Use of subconjunctival cyclosporine implants for treatment of feline eosinophilic keratoconjunctivitis: A case report.

Willems Lynn L, Roberts Jordan K JK

A 5-year-old, neutered male domestic shorthair cat was presented for evaluation of chronic bilateral eosinophilic keratoconjunctivitis (EK). The patient had a history of recurrent corneal plaques and conjunctivitis that were initially managed with systemic and topical immunosuppressive therapy. Long-term disease control was limited by poor tolerance of topical ophthalmic medications, resulting in inconsistent treatment and repeated disease recurrence affecting both eyes. Over several years, the cat was treated with subconjunctival triamcinolone acetonide, antiviral therapy, and topical megestrol acetate, with only partial and temporary improvement. As a result of persistent disease and inability to administer long-term topical therapy reliably, bilateral subconjunctival cyclosporine implants were surgically placed. Postoperative management included short-term topical antibiotic therapy. At 10-week and 7-month postoperative examinations, marked clinical improvement was observed, with resolution of most corneal plaques and substantial reduction in conjunctival inflammation. Feline EK is a chronic immune-mediated ocular surface disease that typically requires long-term topical immunosuppressive therapy. Successful management may be limited in patients who are resistant to medication administration. This case demonstrates that subconjunctival cyclosporine implants may represent a viable long-acting treatment option for feline EK when topical therapy cannot be consistently administered. To the authors' knowledge, the use of cyclosporine implants for the management of feline EK has not previously been reported.

PMID 43048052
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多tacrolimus